NeuroBo Pharmaceuticals Inc. (NRBO): Price and Financial Metrics


NeuroBo Pharmaceuticals Inc. (NRBO): $0.43

0.00 (0.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NRBO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NRBO Stock Price Chart Interactive Chart >

Price chart for NRBO

NRBO Price/Volume Stats

Current price $0.43 52-week high $6.57
Prev. close $0.43 52-week low $0.38
Day low $0.43 Volume 94,300
Day high $0.45 Avg. volume 457,489
50-day MA $0.72 Dividend yield N/A
200-day MA $1.65 Market Cap 11.50M

NeuroBo Pharmaceuticals Inc. (NRBO) Company Bio


NeuroBo Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals conducts business in the United States.


NRBO Latest News Stream


Event/Time News Detail
Loading, please wait...

NRBO Latest Social Stream


Loading social stream, please wait...

View Full NRBO Social Stream

Latest NRBO News From Around the Web

Below are the latest news stories about NeuroBo Pharmaceuticals Inc that investors may wish to consider to help them evaluate NRBO as an investment opportunity.

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directors, effective as of January 27, 2022. Mr. Strickland will serve as Chair of the Company's Audit Committee.

Yahoo | January 28, 2022

10 Low-Float Penny Stocks for Steel-Gutted Investors

If you’re willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill.

Josh Enomoto on InvestorPlace | January 11, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | January 5, 2022

NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2021.

Yahoo | November 15, 2021

NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced that the Company has appointed Gil Price, M.D. as President and Chief Executive Officer. Dr. Price will replace Dr. Richard J. Kang, Ph.D., who is stepping down later this month to pursue other opportunities, while remaining on the Board of Directors. In the inte

Yahoo | November 4, 2021

Read More 'NRBO' Stories Here

NRBO Price Returns

1-mo -26.14%
3-mo -44.55%
6-mo -75.84%
1-year -85.27%
3-year -98.30%
5-year -99.84%
YTD -64.75%
2021 -76.76%
2020 -40.00%
2019 -56.79%
2018 -89.80%
2017 1.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9075 seconds.